Paper Details

  1. Home
  2. Paper Details

Folic Acid Functionalized Diallyl Trisulfide-Solid Lipid Nanoparticles for Targeting Triple Negative Breast Cancer.

Author: BhuyanNihar Ranjan, DeAnindita, DuaKamal, KoYoung Tag, KuppusamyGowthamarajan, RoychowdhuryParikshit, SinghSachin Kumar

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Folic acid-conjugated DATS-SLNs are a promising therapeutic strategy for treating triple-negative breast cancer (TNBC). The study found that FA-DATS-SLNs were more effective in treating TNBC than DATS alone. This is likely due to the increased cellular internalization and efficient Bcl2 protein downregulation that were observed with FA-DATS-SLNs.
Paper Details　
Original Abstract of the Article :
DATS (diallyl trisulfide), an anti-oxidant and cytotoxic chemical derived from the plant garlic, has been found to have potential therapeutic activity against triple-negative breast cancer (TNBC). Its hydrophobicity, short half-life, lack of target selectivity, and limited bioavailability at the tum...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921651/

データ提供：米国国立医学図書館（NLM）

Folic Acid Functionalized Diallyl Trisulfide-Solid Lipid Nanoparticles for Targeting Triple Negative Breast Cancer

This study explores a novel approach for targeting triple-negative breast cancer (TNBC) using diallyl trisulfide (DATS), a compound derived from garlic, encapsulated in folic acid-functionalized solid lipid nanoparticles (FA-DATS-SLNs). The study investigates the effectiveness of this nanoformulation in enhancing DATS delivery and improving its therapeutic efficacy against TNBC.

FA-DATS-SLNs for TNBC Treatment

The study demonstrates the potential of FA-DATS-SLNs in enhancing the therapeutic efficacy of DATS against TNBC. The nanoformulation effectively targets TNBC cells through folate receptor-mediated uptake, improving drug delivery and reducing off-target effects. It's like using a guided missile to precisely target a hidden oasis in a vast desert, maximizing effectiveness and minimizing collateral damage.

Enhanced Anticancer Efficacy

The study highlights the significant anticancer efficacy of FA-DATS-SLNs compared to DATS alone. The nanoformulation promotes greater cellular internalization and efficient downregulation of Bcl2 protein, a key regulator of cell survival, leading to enhanced tumor cell death. This is like employing a more potent weapon in the fight against a formidable foe, increasing the chances of success in battling the disease.

Dr. Camel's Conclusion

This study presents a promising new approach for treating TNBC, demonstrating the potential of FA-DATS-SLNs to improve drug delivery and enhance therapeutic efficacy. It's a beacon of hope in the ongoing battle against cancer, like discovering a hidden spring in a desolate desert, offering a source of life and healing.

Date :
  1. Date Completed 2023-02-14
  2. Date Revised 2023-02-14
Further Info :

Pubmed ID

36771058

DOI: Digital Object Identifier

PMC9921651

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.